A Randomized, Double-blind, Placebo-controlled Clinical Study of the Oral IL-12/23 Inhibitor, STA-5326 Mesylate, Administered to Patients With Rheumatoid Arthritis to Determine Safety, Tolerability, Pharmacokinetic and Synovial Tissue Outcomes
Latest Information Update: 03 Nov 2021
At a glance
- Drugs Apilimod dimesylate (Primary)
- Indications Rheumatoid arthritis
- Focus Pharmacodynamics
- Sponsors Synta Pharmaceuticals
- 14 Dec 2011 Results pertaining to the increased dosage published in Arthritis and Rheumatism.
- 24 Jan 2011 Primary endpoint 'Inflammatory-markers' has not been met
- 24 Jan 2011 Primary endpoint 'Response' has not been met